CA
NZ
UK
AU
IND
US
…
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M |
| Net income | -114.20M | -147.79M | -84.03M | -142.88M | -71.98M |
| Selling general administrative | 52.90M | 54.22M | 47.29M | 46.55M | 43.77M |
| Selling and marketing expenses | - | - | 13.43M | - | - |
| Gross profit | 76.55M | 9.49M | 14.02M | 15.92M | 37.70M |
| Reconciled depreciation | 12.61M | 12.68M | 12.31M | 8.72M | 7.87M |
| Ebit | -102.00M | -134.52M | -70.78M | -116.36M | -73.19M |
| Ebitda | -89.40M | -121.69M | -57.05M | -115.58M | -72.98M |
| Depreciation and amortization | 12.61M | 12.83M | 13.73M | 0.78M | 0.21M |
| Non operating income net other | - | - | - | -8.68M | -6.08M |
| Operating income | -105.97M | -164.21M | -137.06M | -116.36M | -73.19M |
| Other operating expenses | 187.36M | 197.49M | 151.08M | 132.28M | 110.89M |
| Interest expense | 12.20M | 13.27M | 13.24M | 4.95M | 0.29M |
| Interest income | 1.82M | 4.14M | 2.15M | 0.78M | 0.21M |
| Net interest income | -10.38M | -9.13M | -10.54M | -4.17M | -0.08M |
| Income tax expense | - | - | 13.56M | 13.26M | -7.58M |
| Total revenue | 81.39M | 33.28M | 14.02M | 15.92M | 37.70M |
| Total operating expenses | 182.52M | 173.70M | 151.08M | 132.28M | 110.89M |
| Cost of revenue | 4.84M | 23.79M | 13.73M | - | - |
| Total other income expense net | -8.23M | 16.42M | 53.03M | -13.26M | -6.37M |
| Net income from continuing ops | -114.20M | -147.79M | -131.56M | -129.98M | -79.56M |
| Net income applicable to common shares | - | - | - | -129.62M | -79.56M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 244.43M | 269.75M | 458.17M | 318.24M | 320.16M |
| Intangible assets | 0.58M | 0.82M | 1.12M | 2.08M | 2.57M |
| Other current assets | 7.54M | 8.85M | 6.64M | 1.67M | 2.42M |
| Total liab | 250.22M | 201.92M | 319.99M | 200.50M | 134.76M |
| Total stockholder equity | -5.79M | 67.83M | 138.18M | 117.74M | 185.40M |
| Deferred long term liab | - | - | - | 0.19M | 0.78M |
| Other current liab | 83.18M | 28.32M | 43.92M | 46.45M | 27.59M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -816.22M | -702.02M | -554.23M | -470.20M | -340.59M |
| Other liab | - | - | - | 30.06M | 46.28M |
| Other assets | - | - | - | 2.14M | 2.19M |
| Cash | 65.93M | 103.66M | 129.57M | 115.52M | 137.70M |
| Total current liabilities | 122.56M | 60.78M | 67.08M | 82.07M | 68.13M |
| Current deferred revenue | 1.78M | 4.83M | 2.93M | 15.12M | 21.82M |
| Net debt | 22.75M | -18.86M | -40.30M | -23.27M | -113.97M |
| Short term debt | 27.54M | 4.05M | 4.19M | 3.88M | 3.37M |
| Short long term debt | 24.65M | - | - | - | - |
| Short long term debt total | 88.69M | 84.80M | 89.26M | 92.25M | 23.73M |
| Other stockholder equity | 808.02M | 773.57M | 693.84M | 581.89M | 528.66M |
| Property plant equipment | - | - | - | 109.27M | 126.29M |
| Total current assets | 91.76M | 123.52M | 159.62M | 154.34M | 183.24M |
| Long term investments | 6.75M | 6.75M | 6.77M | 6.33M | 6.66M |
| Net tangible assets | - | - | - | 116.40M | 183.61M |
| Net receivables | 18.29M | 10.63M | 23.41M | 29.02M | 35.02M |
| Long term debt | 49.69M | 73.22M | 72.12M | 71.30M | 0.95M |
| Inventory | 0.00M | 0.39M | - | 8.13M | 8.10M |
| Accounts payable | 10.07M | 23.59M | 16.04M | 16.62M | 15.35M |
| Accumulated other comprehensive income | 2.41M | -3.72M | -1.44M | 6.05M | -2.67M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -470.20M | -340.59M |
| Non currrent assets other | 3.41M | 3.01M | 1.92M | 1.22M | 1.21M |
| Non current assets total | 152.67M | 146.23M | 298.55M | 163.90M | 136.92M |
| Capital lease obligations | 14.35M | 11.58M | 17.14M | 21.21M | 23.73M |
| Long term debt total | - | - | - | 71.30M | 0.95M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 23.48M | -25.64M | -44.96M | -6.50M |
| Change to liabilities | - | - | - | 4.43M | 13.96M |
| Total cashflows from investing activities | -4.11M | 23.48M | 34.03M | -44.96M | -61.72M |
| Net borrowings | -0.03M | 0.00M | 0.00M | 75.00M | -0.00M |
| Total cash from financing activities | 12.27M | 54.53M | 84.02M | 95.20M | 1.71M |
| Change to operating activities | - | - | - | 16.63M | 8.72M |
| Net income | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M |
| Change in cash | -37.48M | -24.98M | 15.13M | -22.19M | -71.82M |
| Begin period cash flow | 105.67M | 130.65M | 115.52M | 137.70M | 209.52M |
| End period cash flow | 68.19M | 105.67M | 130.65M | 115.52M | 137.70M |
| Total cash from operating activities | -46.36M | -104.50M | -105.36M | -73.10M | -10.53M |
| Issuance of capital stock | 15.07M | 59.39M | 86.95M | 25.00M | 0.00M |
| Depreciation | 12.70M | 12.68M | 13.72M | 8.72M | 7.87M |
| Other cashflows from investing activities | -0.28M | 28.43M | 54.21M | - | -8.87M |
| Dividends paid | - | - | 0.00M | 0.00M | - |
| Change to inventory | 0.43M | -0.39M | 0.00M | - | 9.03M |
| Change to account receivables | -7.27M | 9.43M | 4.83M | 1.03M | 16.39M |
| Sale purchase of stock | - | - | -1.52M | 0.23M | 1.71M |
| Other cashflows from financing activities | -3.03M | -4.86M | -7.93M | 70.20M | 1.71M |
| Change to netincome | - | - | - | 28.62M | 27.14M |
| Capital expenditures | 3.83M | 4.96M | 20.17M | 44.96M | 55.22M |
| Change receivables | - | - | - | - | 16.39M |
| Cash flows other operating | - | - | - | 14.74M | 3.67M |
| Cash and cash equivalents changes | - | - | - | -22.86M | -70.54M |
| Change in working capital | 28.03M | 29.64M | -0.98M | 9.62M | 31.28M |
| Stock based compensation | 22.11M | 25.19M | 27.72M | 28.62M | 20.78M |
| Other non cash items | 5.01M | -24.22M | -61.80M | 9.55M | 2.74M |
| Free cash flow | -50.19M | -109.45M | -125.54M | -118.06M | -65.75M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings PLC |
0.11 1.16% |
9.63 | 14.67 | 64.10 | 3.08 | 5.74 | 3.04 | 11.40 |
| NVO Novo Nordisk A/S |
2.50 6.21% |
42.69 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.19 3.43% |
548.95 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-29.09 2.99% |
944.27 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Dr. Alexandria Forbes | CEO, Pres & Director | 1965 |
| Mr. Richard Brian Giroux B.A. | COO & CFO | 1973 |
| Dr. Robert K. Zeldin M.D. | Chief Medical Officer | 1963 |
| Mr. Robert J. Wollin J.D. | Gen. Counsel & Sec. | 1977 |
| Dr. Stuart Naylor Ph.D. | Chief Devel. Officer | 1963 |
| Dr. Michel Michaelides M.D. | Head of Clinical Ophthalmology | NA |
| Ms. Christine Elise Sheehy | Sr. VP of Global Integration | 1967 |
| Mr. Joel P. Brooks | Sr. VP of Fin. | 1959 |
| Mr. Tim Randall | Sr. VP of Risk & Internal Controls | NA |
| Dr. Alastair Leighton Ph.D. | Sr. VP of Manufacturing & Supply Chain | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.05%
Communication Services
+1.63%
Consumer Cyclical
+2.50%
Consumer Defensive
+1.82%
Energy
-3.09%
Financial Services
+1.35%
Financials
-5.92%
Healthcare
+2.00%
Industrials
+0.03%
Real Estate
+1.35%
Technology
+0.01%
Utilities
+0.77%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...